Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

WaferGen Biosystems first-quarter revenues increase to $389,785

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today reported performance results for the first quarter ended March 31, 2010.

17 May 2010

Caliper Life Sciences' CDAS unit awarded new funding commitment for EPA ToxCast screening program

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $2.9 million under its contract with the Environmental Protection Agency for the EPA's ToxCast screening program.

14 May 2010

Tripos releases SYBYL-X 1.1 molecular modeling suite

Tripos®, a leading provider of drug discovery informatics products and services, today announced the release and general availability of SYBYL-X Version 1.1. This new release focuses on enhancing research productivity for scientists in the pharmaceutical, agrochemical, flavors and fragrances, and related industries, featuring faster navigation, new menus and toolbars, and new ways to approach life science molecular discovery projects. Previous SYBYL versions have been the benchmark for the industry in molecular modeling, and customers using this new, next generation version have given it high marks.

13 May 2010

Evotec first-quarter operating loss decreases 93% to € 1.5 m

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

12 May 2010

Academic scientist receives $125,000 from ADDF/LBDA program to study LBD

The Alzheimer's Drug Discovery Foundation and the Lewy Body Dementia Association announced today the recipient of their first partnership research award through the Lewy Body Dementia Biomarker Research Program.

12 May 2010

NiKem Research receives Italian authorization to perform toxicology studies of NCEs in rodents

NiKem Research is pleased to announce that it has received on March 29th 2010, from the Italian Ministry of Health (Decree N. 69/2010-B), the authorization to perform acute and sub-chronic toxicology studies (upto 28 days) in all rodent species for preliminary safety evaluation of novel chemical entities (NCEs). Toxicokinetic (TK) studies are also allowed to correlate plasma and/or organ exposure of NCEs (and metabolites) to tolerated doses in toxicology studies.

12 May 2010

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced the launch of the OptiDDITM Suite, a novel assay panel that assesses the most clinically significant transporter-related drug-drug interactions (DDIs), as identified by the International Transporter Consortium (ITC) in its report "Membrane Transporters in Drug Development" (Nature Reviews-Drug Discovery, March 2010).

12 May 2010

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma.

12 May 2010

MaxCyte STX Scalable Transfection System acquired by CCS Cell Culture Service

MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is pleased to announce that CCS Cell Culture Service GmbH has acquired the MaxCyte® STX™ Scalable Transfection System to develop and optimize cells for the pharmaceutical industry.

12 May 2010

ACADIA Pharmaceuticals reports increased revenue in first-quarter 2010

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the first quarter ended March 31, 2010.

11 May 2010

Evotec and Genentech sign drug discovery deal

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group (SWX:RO) (SIX:ROG) (Pink Sheets:RHHBY), to discover novel small molecule therapeutics.

10 May 2010

Findings may help develop a new class of drugs for diabetes

More than half a century after researchers identified a promising way to treat diabetes based on blocking the breakdown of insulin in the body, a research team led by a scientist at the Mayo Clinic campus in Florida have developed potent molecules that can do just that.

10 May 2010

MIT, South Africa announce plans to join patent pool for 'neglected diseases'

Massachusetts Institute of Technology (MIT) and South Africa's Technology Innovation Agency (TIA) will join the Pool for Open Innovation against Neglected Tropical Diseases, Science|Business reports.

10 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

CDI, iPS Academia Japan announce licensing agreement for seminal iPSC patent portfolio

Cellular Dynamics International, Inc. (CDI), the world's largest producer of cellular tools for drug discovery and safety derived from induced pluripotent stem cells (iPSCs), and iPS Academia Japan, Inc., today announced a nonexclusive licensing agreement for the seminal iPSC patent portfolio arising out of the work of Dr. Shinya Yamanaka, M.D., Ph.D., Center for iPS Cell Research and Application (CiRA), Kyoto University.

7 May 2010

CombinatoRx reports $41.3M total revenue for first-quarter 2010

CombinatoRx, Incorporated today reported financial results for the first quarter ended March 31, 2010.

6 May 2010

Scientists catch new mediators to develop novel treatments for diseases linked to inflammatory processes

Scientists at the University of Pittsburgh School of Medicine went on a molecular fishing trip and netted a catch of new mediators that not only can explain how omega-3 fatty acids reduce inflammation, but also hint at novel treatments for a host of diseases linked to inflammatory processes. Their findings were published today in the online version of Nature Chemical Biology.

6 May 2010

GENFIT announces milestone as compound developed in partnership enters the clinic

GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.

6 May 2010

AMRI first-quarter total revenue down 9% to $49.3 million

AMRI today reported financial and operating results for the first quarter ended March 31, 2010.

5 May 2010

MicroStockProfit.com: CRXX's total revenues reach $8.6M in fourth-quarter 2009

MicroStockProfit.com announces an investment report featuring CombinatoRx Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

5 May 2010